Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation

Int J Clin Pharmacol Ther. 2004 Nov;42(11):654-5. doi: 10.5414/cpp42654.

Authors

R A Hilger¹, J Baumgart, M E Scheulen, R Trenschel, D Strumberg, S Seeber, D W Beelen

Affiliation

¹ Department of Internal Medicine (Cancer Research), University of Essen Medical School, West German Cancer Center, Essen, Germany. ralf.hilger@uni-essen.de

PMID: 15598037
DOI: 10.5414/cpp42654

No abstract available

MeSH terms

Antineoplastic Agents, Alkylating / pharmacokinetics
Antineoplastic Agents, Alkylating / therapeutic use*
Area Under Curve
Busulfan / analogs & derivatives*
Busulfan / pharmacokinetics*
Busulfan / therapeutic use
Cyclophosphamide / therapeutic use*
Half-Life
Hematopoietic Stem Cell Transplantation
Humans
Leukemia / therapy*
Metabolic Clearance Rate
Myeloablative Agonists / therapeutic use
Tissue Distribution
Transplantation Conditioning

Substances

Antineoplastic Agents, Alkylating
Myeloablative Agonists
Cyclophosphamide
treosulfan
Busulfan